• Journal for ImmunoTherapy of Cancer (2026) – In collaboration with 4basebio, Neomatrix demonstrated the immunogenicity and anti-tumor activity of a novel synthetic high-performance DNA (hpDNA™) platform, supporting the clinical development of next-generation neoantigen-based immunotherapies.
• Molecular Therapy Oncology (2026) – Neomatrix reported that electroporation-mediated delivery of plasmid DNA can generate a sustained local depot effect, resulting in durable immune responses and providing new insights into the mechanisms underlying plasmid DNA-based cancer therapies.